Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles
0301 basic medicine
Heterozygote
610
Severity of Illness Index
Article
3. Good health
03 medical and health sciences
Amino Acid Substitution
Gene Frequency
Psychotic Disorders
HLA-B Antigens
Case-Control Studies
616
Odds Ratio
HLA-DQ beta-Chains
Humans
Exome
Genetic Predisposition to Disease
Clozapine
Alleles
Agranulocytosis
Antipsychotic Agents
Genome-Wide Association Study
DOI:
10.1038/ncomms5757
Publication Date:
2014-09-04T14:19:45Z
AUTHORS (31)
ABSTRACT
Clozapine is a particularly effective antipsychotic medication but its use is curtailed by the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated individuals. Identifying genetic risk factors for CIAG could enable safer and more widespread use of clozapine. Here we perform the largest and most comprehensive genetic study of CIAG to date by interrogating 163 cases using genome-wide genotyping and whole-exome sequencing. We find that two loci in the major histocompatibility complex are independently associated with CIAG: a single amino acid in HLA-DQB1 (126Q) (P=4.7×10−14, odds ratio, OR=0.19, 95% CI 0.12–0.29) and an amino acid change in the extracellular binding pocket of HLA-B (158T) (P=6.4×10−10, OR=3.3, 95% CI 2.3–4.9). These associations dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug responses for other medications, and provide insight into the pathophysiology of CIAG.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (154)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....